Skip to main content
SpringerLink
Log in

Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force

  • Special Article
  • Published:
The Journal of Frailty & Aging Aims and scope Submit manuscript

Abstract

Establishment of an ICD-10-CM code for sarcopenia in 2016 was an important step towards reaching international consensus on the need for a nosological framework of age-related skeletal muscle decline. The International Conference on Frailty and Sarcopenia Research Task Force met in April 2017 to discuss the meaning, significance, and barriers to the implementation of the new code as well as strategies to accelerate development of new therapies. Analyses by the Sarcopenia Definitions and Outcomes Consortium are underway to develop quantitative definitions of sarcopenia. A consensus conference is planned to evaluate this analysis. The Task Force also discussed lessons learned from sarcopenia trials that could be applied to future trials, as well as lessons from the osteoporosis field, a clinical condition with many constructs similar to sarcopenia and for which ad hoc treatments have been developed and approved by regulatory agencies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cesari M, Fielding R, Benichou O, et al. Pharmacological Interventions in Frailty and Sarcopenia: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging. 2015;4(3):114–20.

    PubMed  PubMed Central  CAS  Google Scholar 

  2. Anker SD, Morley JE, von Haehling S. Welcome to the ICD-10 code for sarcopenia. J Cachexia Sarcopenia Muscle. 2016;7(5):512–4.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Studenski SA, Peters KW, Alley DE, Cawthon PM, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. 2014;69(5):547–58.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cummings SR, Studenski S, Ferrucci L. A diagnosis of dismobility—giving mobility clinical visibility: a Mobility Working Group recommendation. JAMA. 2014;311(20):2061–2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Masanes F, Rojano I. Luque X, et al. Cut-off points for muscle mass — not grip strength or gait speed — determine variations in sarcopenia prevalence. J Nutr Health Aging. 2016.

    Google Scholar 

  7. Batsis JA, Mackenzie TA, Jones JD, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity and inflammation: Results from the 1999-2004 National Health and Nutrition Examination Survey. Clin Nutr. 2016.

    Google Scholar 

  8. Batsis JA, Mackenzie TA, Lopez-Jimenez F, Bartels SJ. Sarcopenia, sarcopenic obesity, and functional impairments in older adults: National Health and Nutrition Examination Surveys 19992004. Nutr Res. 2015;35(12):1031–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Wannamethee SG, Atkins JL. Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc. 2015;74(4):405–12.

    Article  PubMed  Google Scholar 

  10. Pena Ordonez GG, Bustamante Montes LP, Ramirez Duran N, Sanchez Castellano C, Cruz-Jentoft AJ. Populations and outcome measures used in ongoing research in sarcopenia. Aging Clin Exp Res. 2016.

    Google Scholar 

  11. Thomas DK, Quinn MA, Saunders DH, Greig CA. Protein Supplementation Does Not Significantly Augment the Effects of Resistance Exercise Training in Older Adults: A Systematic Review. J Am Med Dir Assoc. 2016;17(10):959 e1–9.

    Article  Google Scholar 

  12. Lozano-Montoya I, Correa-Perez A, Abraha I, et al. Nonpharmacological interventions to treat physical frailty and sarcopenia in older patients: a systematic overview - the SENATOR Project ONTOP Series. Clin Interv Aging. 2017;12:721–40.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Pahor M, Guralnik JM, Ambrosius WT, et al. Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial. JAMA. 2014;311(23):2387–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  14. Landi F, Cesari M, Calvani R, et al. The «Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies» (SPRINTT) randomized controlled trial: design and methods. Aging Clin Exp Res. 2017;29(1):89–100.

    Article  PubMed  Google Scholar 

  15. Cesari M, Landi F, Calvani R, et al. Rationale for a preliminary operational definition of physical frailty and sarcopenia in the SPRINTT trial. Aging Clin Exp Res. 2017;29(1):81–8.

    Article  PubMed  Google Scholar 

  16. Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012;96(6):1454–64.

    Article  PubMed  CAS  Google Scholar 

  17. Cawood AL, Elia M, Stratton RJ. Systematic review and meta-analysis of the effects of high protein oral nutritional supplements. Ageing Res Rev. 2012;11(2):278–96.

    Article  PubMed  CAS  Google Scholar 

  18. Bauer JM, Verlaan S, Bautmans I, et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial. J Am Med Dir Assoc. 2015;16(9):740–7.

    Article  PubMed  Google Scholar 

  19. Cramer JT, Cruz-Jentoft AJ, Landi F, et al. Impacts of HighProtein Oral Nutritional Supplements Among Malnourished Men and Women with Sarcopenia: A Multicenter, Randomized, Double-Blinded, Controlled Trial. J Am Med Dir Assoc. 2016;17(11):1044–55.

    Article  PubMed  Google Scholar 

  20. Tieland M, Dirks ML, van der Zwaluw N, et al. Protein supplementation increases muscle mass gain during prolonged resistance-type exercise training in frail elderly people: a randomized, double-blind, placebocontrolled trial. J Am Med Dir Assoc. 2012;13(8):713–9.

    Article  PubMed  Google Scholar 

  21. Tieland M, van de Rest O, Dirks ML, et al. Protein supplementation improves physical performance in frail elderly people: a randomized, doubleblind, placebo-controlled trial. J Am Med Dir Assoc. 2012;13(8):720–6.

    Article  PubMed  Google Scholar 

  22. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56.

    Article  PubMed  CAS  Google Scholar 

  23. Cooper R, Kuh D, Cooper C, et al. Objective measures of physical capability and subsequent health: a systematic review. Age Ageing. 2011;40(1):14–23.

    Article  PubMed  Google Scholar 

  24. Simmonds SJ, Syddall HE, Westbury LD, Dodds RM, Cooper C, Aihie Sayer A. Grip strength among community-dwelling older people predicts hospital admission during the following decade. Age Ageing. 2015;44(6):954–9.

    Article  PubMed  Google Scholar 

  25. Beaudart C, Biver E, Reginster JY, et al. Validation of the SarQoL(R), a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2017;8(2):238–44.

    Article  PubMed  Google Scholar 

  26. Beaudart C, Biver E, Reginster JY, et al. Development of a selfadministrated quality of life questionnaire for sarcopenia in elderly subjects: the SarQoL. Age Ageing. 2015;44(6):960–6.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Vellas B, Balardy L, Gillette-Guyonnet S, et al. Looking for frailty in community-dwelling older persons: the Gerontopole Frailty Screening Tool (GFST). J Nutr Health Aging. 2013;17(7):629–31.

    Article  PubMed  CAS  Google Scholar 

  28. Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36.

    Article  PubMed  Google Scholar 

  29. Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging. 2012;16(7):601–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Janssen I, Heymsfield SB, Wang ZM, Ross R. Skeletal muscle mass and distribution in 468 men and women aged 18-88 yr. J Appl Physiol (1985). 2000;89(1):81–8.

    Article  CAS  Google Scholar 

  31. Saini A, Faulkner S, Al-Shanti N, Stewart C. Powerful signals for weak muscles. Ageing Res Rev. 2009;8(4):251–67.

    Article  PubMed  CAS  Google Scholar 

  32. Vellas B, Fielding R, Bhasin S, et al. Sarcopenia Trials in Specific Diseases: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging. 2016;5(4):194–200.

    PubMed  CAS  Google Scholar 

  33. Fougere B, Boulanger E, Nourhashemi F, Guyonnet S, Cesari M. Chronic Inflammation: Accelerator of Biological Aging. J Gerontol A Biol Sci Med Sci. 2016.

    Google Scholar 

  34. Reginster JY, Cooper C, Rizzoli R, et al. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia. Aging Clin Exp Res. 2016;28(1):47–58.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UMR1027 Inserm, Toulouse, France

    Bruno Vellas

  2. University of Toulouse III, Toulouse, France

    Bruno Vellas

  3. Gérontopôle Toulouse, Toulouse University Hospital, Toulouse, France

    Bruno Vellas

  4. Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA

    R. A. Fielding

  5. Alliance for Aging Research, Aging in Motion (AIM), Washington, DC, USA

    C. Bens

  6. Fondation Policlinico A. Gemelli, Roma, Italy

    R. Bernabei

  7. Research Institute, California Pacific Medical Center, San Francisco, CA, USA

    P. M. Cawthon

  8. Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

    P. M. Cawthon

  9. Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University, and Department of Geriatrics, Uppsala University Hospital, Uppsala, Sweden

    T. Cederholm

  10. Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain

    A. J. Cruz-Jentoft

  11. Boiphytis, Paris, France

    S. Del Signore

  12. Bluecompanion Ltd, London, UK

    S. Del Signore

  13. Regneron, Tarrytown, NY, USA

    S. Donahue

  14. Division of Geriatric St. Louis, University Medical School, St. Louis, MO, USA

    J. Morley

  15. Institute on Aging, University of Florida, Gainesville, FL, USA

    M. Pahor

  16. University of Liege, Liege, Belgium

    J.-Y. Reginster

  17. Jefe de Servicio de Geriatría, Hospital Universitario de Getafe, Toledo, Spain

    L. Rodriguez Mañas

  18. Service de Médecine Interne et Gérontologie, Clinique Gérontopôle, Hôpital La Crave, Casselardit, Toulouse, France

    Y. Rolland

  19. Novartis Institutes for Biomedical Research, Basel, Switzerland

    R. Roubenoff

  20. Diabetes and Geriatric Research Unit, University of Luton, Luton, UK

    A. Sinclair

  21. Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

    M. Cesari

  22. Université de Toulouse III Paul Sabatier, Toulouse, France

    M. Cesari

Authors
  1. Bruno Vellas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. A. Fielding
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Bens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Bernabei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P. M. Cawthon
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. T. Cederholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. J. Cruz-Jentoft
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S. Del Signore
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S. Donahue
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. J. Morley
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M. Pahor
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J.-Y. Reginster
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. L. Rodriguez Mañas
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Y. Rolland
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. R. Roubenoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. A. Sinclair
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M. Cesari
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The International Conference on Frailty and Sarcopenia Research Task Force

Corresponding author

Correspondence to Bruno Vellas.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vellas, B., Fielding, R.A., Bens, C. et al. Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J Frailty Aging 7, 2–9 (2018). https://doi.org/10.14283/jfa.2017.30

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.14283/jfa.2017.30

Key words

Search

Navigation